Z-526 alleviates chemotherapy-induced cachexia muscle atrophy in vivo
Aug. 2, 2024
Researchers from East China Normal University and Fudan University presented the discovery of a new oral compound, Z-526, being developed as a treatment to alleviate chemotherapy-induced cachectic muscle loss.